Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

9480	Companies
185543	Keywords
117939	Articles
99384	Press releases

Home
Companies
Biophytis

REGULATED PRESS RELEASE

published on 06/10/2024 at 08:18, 1 year 5 months ago

Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity
Biophytis files IND application with US FDA for phase 2 obesity study with BIO101 (20-hydroxyecdysone) to assess muscle strength improvement in lower limbs and secondary endpoints like mobility and body composition

FDA Biophytis BIO101 IND Application Obesity Study
PRESS RELEASE

published on 06/10/2024 at 08:16, 1 year 5 months ago

Biophytis announces filing of an IND application with the US FDA for its phase 2 study in obesity
Biophytis submits IND application to US FDA for phase 2 obesity study with BIO101 (20-hydroxyecdysone). Study to assess muscle strength & body composition. Research led by Professor Marc-André Cornier

Biophytis BIO101 IND Application Obesity Study Professor Marc-André Cornier
BRIEF

published on 06/07/2024 at 08:28, 1 year 5 months ago

Biophytis Announces Combined General Meeting on June 24, 2024

Shareholders Biophytis General Meeting Voting Agenda
REGULATED PRESS RELEASE

published on 06/07/2024 at 08:23, 1 year 5 months ago

Combined General Meeting of June 24, 2024
Biophytis SA to hold Combined General Meeting (CGM) on June 24, 2024 in Paris. Shareholders encouraged to vote in advance via multiple methods. Details available on the company's website

Shareholders Voting Combined General Meeting Biophytis SA CGM
BRIEF

published on 06/07/2024 at 07:44, 1 year 5 months ago

Biophytis Combined General Meeting scheduled for June 24, 2024

Shareholders Biophytis Paris General Assembly Vote
PRESS RELEASE

published on 06/07/2024 at 07:39, 1 year 5 months ago

Combined General Meeting of June 24, 2024
Biophytis to hold Combined General Meeting (CGM) on June 24, 2024 at Sorbonne Université. Shareholders urged to vote in advance. Company specializes in age-related disease therapeutics

Shareholders Biophytis Therapeutics Combined General Meeting Age-related Diseases
BRIEF

published on 05/14/2024 at 07:05, 1 year 6 months ago

Biophytis Unveils Phase 2 OBA Clinical Study Design in Obesity

Biophytis Obesity Treatment Clinical Trial BIO101 OBA Clinical Study
PRESS RELEASE

published on 05/14/2024 at 07:00, 1 year 6 months ago

Biophytis announces the design of its phase 2 OBA clinical study in obesity
Biophytis announces the design of its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone), targeting muscle preservation in patients with obesity undergoing weight loss treatment with GLP-1 RAs

Biophytis BIO101 Muscle Preservation Obesity Phase 2 OBA Clinical Study
REGULATED PRESS RELEASE

published on 05/14/2024 at 07:00, 1 year 6 months ago

Biophytis announces the design of its phase 2 OBA clinical study in obesity
Biophytis announces the design of its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone), aiming to test efficacy and safety for muscle function in obese patients. Study to start mid-2024 with results expected in 2025

Biophytis BIO101 Obesity Phase 2 OBA Clinical Study Muscle Function
BRIEF

published on 04/29/2024 at 14:44, 1 year 7 months ago

Biophytis announces the deployment of its partnership strategy in the obesity sector

Strategic Partnerships Biophytis Pharmaceutical BIO101 Obesity

Accesswire

Published on 12/05/2025 at 20:25, 44 minutes ago

The Feedback Loop: Why SMX's Adoption in One Industry Accelerates Interest in All the Others
Published on 12/05/2025 at 20:15, 54 minutes ago

When Proof Becomes Infrastructure, Markets Rewrite the Story (NASDAQ: SMX)
Published on 12/05/2025 at 19:50, 1 hour 19 minutes ago

Gold, Rare Earth Minerals, Digital Assets: The Market Just Realized SMX Sits in All Three
Published on 12/05/2025 at 19:20, 1 hour 49 minutes ago

The Multi-Sector Validation Shock: Why SMX Became Impossible for Markets to Ignore
Published on 12/05/2025 at 18:45, 2 hours 24 minutes ago

Four Global Markets, One Engine: SMX Just Redefined What a Supply Chain Can Prove

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 18:58, 2 hours 11 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 2 hours 43 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 2 hours 54 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:51, 3 hours 17 minutes ago

Issue of Equity
Published on 12/05/2025 at 17:46, 3 hours 23 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds

Les Echos

Published on 12/05/2025 at 17:18, 3 hours 51 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 5 hours 58 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 08:45, 12 hours 24 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 1 day 3 hours ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 1 day 3 hours ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

View all LES ECHOS COMFI WIRE